Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

This study is a multicenter, prospective, randomized, open-label clinical study to assess the efficacy and safety of endocrine combined with different doses and treatment duration of darisenatide adjuvant therapy in HR +/HER2- early breast cancer. The study planned to include 2000 HR +/HER2- early breast cancer patients who met the study criteria and were randomized in a 1:1 ratio to Column 1 and Column 2 stratified by nodal status (positive/negative), prior (neo) adjuvant chemotherapy (yes/no), and clinical/pathological stage (Stage II/III). Cohort 1 received dalcili 125 mg in combination wi

Trial Details

NCT ID
NCT07581834
Phase
PHASE2
Sponsor
Fujian Cancer Hospital
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Dalpiciclib 125mg
  • Dalpiciclib 100mg
  • Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen
Locations (sample)
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • Female aged 18 years or older with breast cancer who are postmenopausal or premenopausal/perimenopausal.
  • Patients with early-stage breast cancer whose HR status is positive and HER2 status is negative, as confirmed by histology (immunohistochemistry sh…
  • Patients with histologically confirmed invasive breast cancer at clinical/pathological stages II-III.
  • Note: For stage IIA, N1 is required, or N0 with Grade 3 or Grade 2 tumors combined with high-risk factors such as Ki-67 ≥20% or positive genetic te…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →